Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

20.90
-0.0400-0.19%
Post-market: 21.660.7636+3.65%19:46 EST
Volume:3.89M
Turnover:81.88M
Market Cap:2.16B
PE:-20.02
High:22.10
Open:20.60
Low:20.54
Close:20.94
52wk High:38.26
52wk Low:20.39
Shares:103.29M
Float Shares:91.60M
Volume Ratio:1.05
T/O Rate:4.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0438
EPS(LYR):-0.8100
ROE:-11.29%
ROA:-19.02%
PB:2.27
PE(LYR):-25.80

Loading ...

Movement Alert|Beam Therapeutics, Inc. Intraday Rise 5.21%, sickle cell therapy progress continues to support sentiment

Market Focus
·
Nov 20

Movement Alert|Beam Therapeutics, Inc. Intraday Rise 5.07%, sickle cell therapy progress continues to support sentiment

Market Focus
·
Nov 19

Movement Alert|Beam Therapeutics, Inc. Intraday Rise 6.83%, sickle cell therapy progress continues to support sentiment

Market Focus
·
Nov 18

Need To Know: The Consensus Just Cut Its Beam Therapeutics Inc. (NASDAQ:BEAM) Estimates For 2027

Simply Wall St.
·
Nov 18

Movement Alert|Beam Therapeutics, Inc. Intraday Decline 9.35%, shares remain under pressure after sickle cell therapy update and wider loss

Market Focus
·
Nov 17

Does Pivotal Sickle Cell Trial Success Change The Bull Case For Beam Therapeutics (BEAM)?

Simply Wall St.
·
Nov 12

Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity

TIPRANKS
·
Nov 11

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Olema Pharmaceuticals (OLMA) and Zentalis Pharmaceuticals (ZNTL)

TIPRANKS
·
Nov 11

Beam Therapeutics (BEAM) Dropped, So What Is Behind The Latest Attention?

Simply Wall St.
·
Nov 11

Analysts’ Top Healthcare Picks: Tecan Group AG (TCHBF), Beam Therapeutics (BEAM)

TIPRANKS
·
Nov 11

Beam Therapeutics reports BEACON trial achieves primary efficacy endpoint

TIPRANKS
·
Nov 11

Beam Therapeutics Reports Positive Pivotal Data for Risto-Cel in Sickle Cell Disease

Reuters
·
Nov 10

Beam Therapeutics - Beacon Trial Meets All Secondary Endpoints Including Freedom from Hospitalization for Vocs

THOMSON REUTERS
·
Nov 10

Beam Therapeutics - Plans Bla Submission for Risto-Cel to FDA Expected by Year-End 2026

THOMSON REUTERS
·
Nov 10

Beam Therapeutics - Beacon Trial Achieves Primary Efficacy and Safety Endpoints for Risto-Cel in Sickle Cell Disease

THOMSON REUTERS
·
Nov 10

Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.
·
Nov 07

Beam Therapeutics Inc. : Jonestrading Assumes Coverage with Buy Rating; Target Price $35

THOMSON REUTERS
·
Nov 05

US Research Roundup-Cencora, Dave, Uber

Reuters
·
Nov 05

Beam Therapeutics Reports Improved Patient-Reported Outcomes in Risto-Cel Sickle Cell Trial

Reuters
·
Nov 04

Clene Posts Q3 Profit on Warrant Liability Gains

Reuters
·
Nov 04